ВПРИВ Uses, Dosage, Side Effects and more
ВПРИВ is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, ВПРИВ has also been investigated for use in Type 3 Gaucher disease.
| Trade Name | ВПРИВ |
| Generic | Velaglucerase alfa |
| Velaglucerase alfa Other Names | GA-GCB, Velaglucerasa alfa, Velaglucerase alfa |
| Type | |
| Formula | C2532H3850N672O711S16 |
| Weight | 63000.0 Da (approximate) |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Russia |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
ВПРИВ is an enzyme replacement therapy used for the long-term treatment of for pediatric and adult patients with type 1 Gaucher disease.
ВПРИВ is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
ВПРИВ is also used to associated treatment for these conditions: Gaucher Disease, Type 1
How ВПРИВ works
ВПРИВ catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.
Food Interaction
No interactions found.Volume of Distribution
The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).
Half Life
11-12 minutes.
Clearance
Mean clearance ranges from 6.72 to 7.56 mL/min/kg.
